文献速递乳腺癌放疗

前瞻性随机SENOMAC试验中放射治疗的质量评估

Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
PubMed 文献 · Radiother Oncol · 2024-06-10

SENOMAC试验将临床淋巴结阴性、1-2枚前哨淋巴结宏转移的乳腺癌患者随机分至完成腋窝淋巴结清扫术或仅前哨淋巴结活检,辅助放疗遵循国家指南;瑞典和丹麦截至2019年6月入组患者的放疗计划与病例报告表一致性极高,Ⅰ水平即使未作为计划靶区也接受高剂量覆盖,将其纳入靶区使肱骨头受量显著增加。

要点

  • 病例报告表与放疗计划在乳腺/胸壁和区域放疗的一致性分别为99.3%和96.6%。
  • Ⅰ水平是否为计划靶区的一致性较低(78%),仅前哨淋巴结活检组更常将其设为靶区(55% vs 31%)。
  • 即使Ⅰ水平未作为计划靶区,其>80%体积仍接受全量照射;将其纳入靶区使肱骨头≥50%体积受量增加一倍以上。

核心结论

  • 病例报告表数据与放疗计划之间的一致性极好。
  • 即使Ⅰ水平未被有意纳入靶区,其仍接受高剂量覆盖。
  • 将Ⅰ水平纳入靶区显著增加了肱骨头的受量。

研究设计与样本

  • SENOMAC试验为前瞻性随机试验,2015-2021年间将临床淋巴结阴性、1-2枚前哨淋巴结宏转移的乳腺癌患者随机分至完成腋窝淋巴结清扫术或仅前哨淋巴结活检。
  • 辅助放疗遵循国家指南;收集瑞典和丹麦截至2019年6月入组患者的放疗计划(N=1176)并与病例报告表比较。
  • 对Ⅰ水平(N=270)和肱骨头(N=321)的剂量进行详细分析。

主要发现

  • 病例报告表数据与放疗计划在乳腺/胸壁的一致性为99.3%,区域放疗的一致性为96.6%。
  • Ⅰ水平是否为计划靶区的一致性较低(78%)。
  • 依照丹麦国家指南,仅前哨淋巴结活检组将Ⅰ水平设为计划靶区的比例(N=334/611,55%)高于腋窝淋巴结清扫组(N=174/565,31%)。
  • 当Ⅰ水平为计划靶区时,其接受处方剂量覆盖的体积为100%(IQR 98-100%);即使未作为计划靶区,其>80%体积(IQR 75-90%)仍接受全量照射。
  • 将Ⅰ水平有意纳入靶区使肱骨头≥50%体积接受的剂量增加一倍以上。

关键数值与推荐

  • 病例报告表与放疗计划在乳腺/胸壁的一致性为99.3%,区域放疗为96.6%。
  • Ⅰ水平作为计划靶区的一致性为78%。
  • 仅前哨淋巴结活检组Ⅰ水平设为靶区为N=334/611(55%),腋窝淋巴结清扫组为N=174/565(31%)。
  • Ⅰ水平为靶区时处方剂量覆盖体积为100%(IQR 98-100%)。
  • Ⅰ水平非靶区时>80%体积(IQR 75-90%)接受全量照射。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Recommendations for regional radiotherapy (RT) of sentinel lymph node (SLN)-positive breast cancer are debated. We here report a RT quality assessment of the SENOMAC trial. MATERIALS AND METHODS: The SENOMAC trial randomized clinically node-negative breast cancer patients with 1-2 SLN macrometastases to completion axillary lymph node dissection (cALND) or SLN biopsy only between 2015-2021. Adjuvant RT followed national guidelines. RT plans for patients included in Sweden and Denmark until June 2019 were collected (N = 1176) and compared to case report forms (CRF). Dose to level I (N = 270) and the humeral head (N = 321) was analyzed in detail. RESULTS: CRF-data and RT plans agreed in 99.3 % (breast/chest wall) and in 96.6 % of patients (regional RT). Congruence for whether level I was an intended RT target was lower (78 %). In accordance with Danish national guidelines, level I was more often an intended target in the SLN biopsy only arm (N = 334/611, 55 %,) than in the cALND arm (N = 174/565, 31 %,). When an intended target, level I received prescribed dose to 100 % (IQR 98-100 %) of the volume. However, even when not an intended target, full dose was delivered to > 80 % of level I (IQR 75-90 %). The intentional inclusion of level I in the target volume more than doubled the dose received by ≥ 50 % of the humeral head. CONCLUSION: Congruence between CRF data and RT plans was excellent. Level I received a high dose coverage even when not intentionally included in the target. Including level I in target significantly increased dose to the humeral head.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Alkner S, Wieslander E, Lundstedt D, et al. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. Radiother Oncol. 2024. PMID: 38866204. doi:10.1016/j.radonc.2024.110372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。